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We present a retrospective analysis on a cohort of low-grade, node-negative patients showing that human epidermal growth factor
receptor 2 (HER2) status significantly affects the survival in this otherwise very good prognostic group. Our results provide support
for the use of adjuvant trastuzumab in patients who are typically classified as having very good prognosis, not routinely offered
standard chemotherapy, and who as such do not fit current UK prescribing guidelines for trastuzumab.
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Human epidermal growth factor receptor 2 (HER2) amplification
has become the prototype biomarker for translation of a laboratory
discovery through to development of a highly successful indivi-
dualised biological therapy agent. Slamon et al (1987) established
HER2 as a poor prognostic marker for survival in breast cancer
and developed a monoclonal antibody, trastuzumab, targeted to
HER2, as a novel therapy for breast cancer patients. More recently,
randomised trials in early breast cancer have shown the clinical
benefit of trastuzumab after chemotherapy with significant overall
survival benefit over chemotherapy alone (Romond et al, 2005;
Slamon et al, 2006; Smith et al, 2007). As a result, trastuzumab has
been introduced into routine clinical practice in the UK for
HER2-positive patients who have completed their standard
adjuvant treatment. Current Scottish and National Institute for
Health and Clinical Excellence (NICE) guidelines parallel the
herceptin adjuvant (HERA) trial entry criteria, according to which
trastuzumab is offered only to those patients who have already
received standard chemotherapy regimes as part of their treatment
regime.
However, there remains a small subset of HER2-positive patients
who are low grade and node negative and who are currently
ineligible for trastuzumab treatment as clinically they have been
deemed to have no requirement for standard adjuvant chemother-
apy. In our region, approximately 25% of HER2 patients are not
offered herceptin as they are deemed to be at ‘low risk’ (personal
communication). Our study analyses a retrospective cohort of low-
grade and node-negative tumours, traditionally classified by
Nottingham Prognostic Index (NPI) and Adjuvant! Online as
‘low risk’ to assess whether HER2 positivity affects survival in this
otherwise very good prognostic group.
METHODS
Patients
We have a large cohort (n¼1351) of breast cancers diagnosed
between 1980–2002 with full clinical follow-up (median 6.5 years)
and pathological details taken from pathology reports. Tissue
specimens from these cancers had been used to create tissue
microarray technology (TMA) for research purposes (ethical
approval was obtained). The grades of tumours from the cohorts
diagnosed in the 1980–90s were reviewed for accuracy by a
consultant pathologist (EAM). From this database, we wished to
identify a group of patients who would classically be identified as
‘low risk’. We selected all node-negative, grade 1 or 2 cancers
(n¼362) for further analysis.
Human epidermal growth factor receptor 2 status
assessment
Human epidermal growth factor receptor 2 status was identified
using currently applicable clinical methodology (Bartlett et al,
2003). Dako Herceptest was used to quantify immunohistochem-
ical staining. All 3þ (high-intensity) staining specimens were
considered positive. All 2þ (moderate-intensity) staining speci-
mens underwent FISH analysis and those who showed HER2
amplification were also classified as positive by the methods
described earlier (Bartlett et al, 2003).
Analysis
SPSS (v15) was used to plot Kaplan–Meier survival curves using
breast cancer-specific death as an outcome endpoint (log-rank
testing). Cox regression analysis was carried out to evaluate the
independence of HER2 in predicting the outcome in conjunction
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swith age, oestrogen receptor (ER), grade, size and endocrine
treatment. Cox regression hazard ratios were obtained for studying
the effect of HER2 status on breast cancer-specific death in the
subcategories split into ER status, age of the patient, and size of
tumour.
RESULTS
Patient characteristics
There were 362 node-negative, grade 1 or 2 cancers available for
analysis. This group contained 90% ER-positive cases, with 71%
having size o20mm. In all, 80% of the patients were aged over 50
years, 10% received chemotherapy and 91% received endocrine
therapy (tamoxifen). Table 1 shows the distribution of clinico-
pathological variables of the good prognostic group split by HER2
status. Fisher’s exact test has been used to compare the variables
between the HER2 positive and -negative groups. The HER2-
positive patients were more likely to be grade 2, ER negative, and
were more likely to have received chemotherapy.
Human epidermal growth factor receptor 2 status and
survival
Sixty-one percent of cases were HER2 positive. In univariate log-rank
testing, HER2-positive patients were significantly more likely to
relapse on tamoxifen, giving 5-year breast cancer-specific survival
rates of 68% compared with 96% for the HER2-negative group
(Po0.001, Figure 1). This significance was retained in Cox regression
analysis when analysed alongside grade, size, ER status, age and
chemotherapy treatment (Po0.001). The overall hazard ratio
for HER2 positivity was 5.65 (95% CI 2.4–13.1, Po0.001). This
reduction in survival in HER2-positive cases persisted when
patients were split into subgroups by ER status, tumour size and
age (Table 2).
DISCUSSION
Our results suggest that no HER2-positive patient should be
classified as at ‘low risk’. We also suggest that our findings
reinforce the importance of having HER2 results available on all
patients at multidisciplinary meetings to enable clinicians to make
informed decisions on outlook and treatment options.
There have been conflicting reports on the effect of HER2 status
in good prognostic groups in the literature. Some have shown
similar prognosis in node-negative patients (Paik et al, 1990a;
Kallioniemi et al, 1991; Quenel et al, 1995; Press et al, 1997;
Andrulis et al, 1998; Harbeck et al, 1999; Schmidt et al, 2005) even
with small (1–10mm) tumours (Joensuu et al, 2003) or ones with
lower grade (Paik et al, 1990b). Other papers have not confirmed
this (Richner et al, 1990; Rosen et al, 1995; Ko et al, 2007),
Table 1 Clinicopathological details
HER2 negative HER2 positive
Comparison using
Number Valid % Number Valid % Fisher’s and v
2*( P values)
Grade
1 112 32.9 2 9.1 0.018
2 228 67.1 20 90.9
ER status
Positive 270 90.9 13 68.4 0.08
Negative 27 9.1 6 31.6
Unknown 43 3
Histological type
Ductal 265 78.2 21 95.5 1.139*
Lobular 39 11.5 1 4.5
Other 35 10.3 0 0.0
Unknown 1 22
Size
T1 (o20mm) 214 70.9 16 76.2 0.84
T2 (20–50mm) 88 29.1 5 23.8
Unknown 1
Age
o50 years 63 18.5 8 36.4 0.252
50–65 years 152 44.7 9 40.9
65+ 125 36.8 5 22.7
Chemotherapy
Yes 27 8.9 6 30.0 0.01
No 276 91.1 14 70.0
Unknown 37 2
Endocrine (mainly tamoxifen)
Yes 277 91.4 19 100.0 0.382
No 26 8.6 0 0.0
Unknown 37 3
Grade¼Bloom and Richardson grade; ER status¼positive or negative for oestrogen receptor immunohistochemical staining; HER2 status¼ positive or negative (as defined in
text), histological type; ductal¼invasive ductal carcinoma; lobular¼invasive lobular carcinoma; other includes mucinous, mucoid, etc.; chemotherapy¼standard chemotherapy
regime at the time of diagnosis. P values for comparison of variables between HER2 positive and negative patients using Fisher’s and w
2* tests.
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salthough care must be undertaken when interpreting earlier
studies, which may not have used the currently accepted methods
of HER2 testing or are underpowered.
Two large studies, conducted recently, add substantial weight
to our findings. In a study of over 2000 node-negative patients
(Chia et al, 2008), HER2 status was shown to be an independent
prognostic factor for disease-free survival in ER-negative patients.
Rakkhit et al (2009) have shown HER2 to be a significant predictor
of disease-free survival in a group of almost 1000 node-negative
tumours o1cm in size.
Our results are in keeping with those from the HERA trial,
which suggested that patients with the best prognosis tumours
(node negative and size 1–2cm) had benefit from herceptin,
similar to the overall cohort (Untch et al, 2008). The 29%
of patients in the BCIRG 006 trial who were node negative
(Slamon et al, 2006) also derived benefits similar to those derived
by the whole cohort using trastuzamab, although they were
included only if they had another high-risk feature (grade, ER
negative over 2cm).
The persistence of a reduction in survival in our HER2positive
or ER-positive subgroup despite endocrine therapy is in keeping
with the recent trans-ATAC (Arimidex, Tamoxifen, Alone or in
Combination) and BIG1–98 analysis based on HER2 status
(Ranganathan et al, 2007) (Rasmussen et al, 2008) and suggests
that we cannot rely solely on adjuvant endocrine therapy
(tamoxifen or aromatase inhibitor) in these largely ER-positive
patients.
Although this study suggests important findings with respect to
HER2 status in good prognosis tumours, we accept the study’s
limitations with respect to the small number of HER2-positive
patients in the cohort. Even within this restricted cohort, HER2-
positive patients were less likely to be grade 1 and more likely to be
ER negative. In addition, sub-analysis was not performed on
tumours o10mm in size because of the small number of tumours
falling into the subgroup.
In conclusion, these results, in the context of other recently
reported retrospective studies and adjuvant trials, provide
support for the rationale of using adjuvant trastuzumab in this
subgroup of patients, who are typically classified as having very
good prognosis. These patients may not be routinely offered
standard chemotherapy, and as such do not fit the current
prescribing guidelines for trastuzumab. A clinical trial to assess the
benefit of adjuvant trastuzumab within this group of HER2
patients would resolve this. Whether trastuzumab would be
effective alone in these patients (without the potential side effects
of standard chemotherapy regimes) deserves investigation. The
combination of hormonal therapy and trastuzumab may be
particularly beneficial in ER-positive patients, because trastuzu-
mab may overcome the crosstalk between the HER and ER
receptors, which is likely responsible for the reduced efficacy of
hormonal therapy in this group.
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Table 2 Subgroup hazard ratio analysis (Cox regression)
Events 95% CI
Number in group HER2 pos HER2 neg (%) P value Hazard ratio Lower Upper
Whole cohort 362 7/22 (31.8) 26/340 (7.6) 0.000 5.65 2.43 13.12
ER positive 283 3/13 (23.1) 17/270 (6.3) 0.010 5.07 1.47 17.51
ER negative 33 3/6 (50) 6/27 (22.2) 0.049 4.41 1.01 19.27
Age o50 71 2/8 (25) 3/63 (4.8) 0.036 8.10 1.14 57.56
Age 50–65 161 3/9 (33.3) 10/152 (6.6) 0.004 6.73 1.84 24.65
Age 465 130 2/5 (40) 13/125 (10) 0.033 5.09 1.14 22.66
Size o20mm 230 5/16 (31.2) 9/214 (4.2) 0.000 8.99 3.00 26.96
Size 420mm 93 2/5 (40) 12/88 (13.6) 0.016 6.93 1.44 33.49
No chemotherapy 290 3/14 (21.4) 13/276 (4.7) 0.010 5.24 1.49 18.40
Chemotherapy 33 2/6 (33.3) 3/27 (11.1) 0.214 3.11 0.52 18.66
No tamoxifen 26 0 4/26 (15.4) n/a
Tamoxifen 296 5/19 (26.3) 12/277 (43.3) 0.000 7.29 2.55 20.78
Hazard ratio¼relative increased hazard with 95% confidence intervals from Cox regression analysis for HER2-positive versus HER2-negative cases; percentages¼percentage
relapse rates in at-risk population. P values are derived from Cox multiple regression analysis with significant hazard ratios shown in bold.
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Figure 1 Kaplan–Meier curves for HER2 status. Survival curves showing
cumulative survival differences (end point¼breast cancer-specific survival)
between patients positive or negative for HER2. P-value represents log-
rank testing of the difference in cumulative survival.
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